PT951908E - Metodo para o tratamento de impotencia devida a lesao da medula espinal - Google Patents

Metodo para o tratamento de impotencia devida a lesao da medula espinal

Info

Publication number
PT951908E
PT951908E PT99301085T PT99301085T PT951908E PT 951908 E PT951908 E PT 951908E PT 99301085 T PT99301085 T PT 99301085T PT 99301085 T PT99301085 T PT 99301085T PT 951908 E PT951908 E PT 951908E
Authority
PT
Portugal
Prior art keywords
spinal cord
lesion
treatment
impotence due
male
Prior art date
Application number
PT99301085T
Other languages
English (en)
Inventor
Maytom Murray Craig
Osterloh Ian Howard
Original Assignee
Pfizer Ireland Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ireland Pharmaceuticals filed Critical Pfizer Ireland Pharmaceuticals
Publication of PT951908E publication Critical patent/PT951908E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Electrotherapy Devices (AREA)
PT99301085T 1998-02-23 1999-02-15 Metodo para o tratamento de impotencia devida a lesao da medula espinal PT951908E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7558098P 1998-02-23 1998-02-23

Publications (1)

Publication Number Publication Date
PT951908E true PT951908E (pt) 2005-01-31

Family

ID=22126701

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99301085T PT951908E (pt) 1998-02-23 1999-02-15 Metodo para o tratamento de impotencia devida a lesao da medula espinal

Country Status (17)

Country Link
US (1) US20060040935A1 (pt)
EP (1) EP0951908B1 (pt)
JP (1) JPH11315025A (pt)
KR (1) KR19990072798A (pt)
AT (1) ATE279194T1 (pt)
AU (1) AU755402B2 (pt)
CA (1) CA2262268C (pt)
DE (1) DE69921008T2 (pt)
DK (1) DK0951908T3 (pt)
ES (1) ES2226281T3 (pt)
HU (1) HUP9900438A3 (pt)
IL (1) IL128532A0 (pt)
MY (1) MY133446A (pt)
NZ (1) NZ334333A (pt)
PT (1) PT951908E (pt)
TW (1) TW542719B (pt)
ZA (1) ZA991393B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
US6200591B1 (en) 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
DE19834506A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Transmucosales therapeutisches System zur Anwendung von Sildenafil
DE19834507A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil
US6613768B1 (en) 1999-04-30 2003-09-02 Lilly Icos Llc Treatment of female arousal disorder
MXPA02006240A (es) 1999-12-24 2003-01-28 Bayer Ag Nuevas imidazo[1,3,5,) triazinonas y su uso.
KR20010016165A (ko) * 2000-11-16 2001-03-05 정순학 성기능 장애 치료를 위한 피부에 적용하는 제제
KR100393160B1 (ko) * 2001-06-14 2003-07-31 한국과학기술연구원 신규한 피라졸로피리미딘티온 유도체, 그의 제법 및발기부전 치료제로서의 용도
EP1404336A1 (en) * 2001-06-14 2004-04-07 Sampad Bhattacharya Compositions comprising cgmppde5 inhibitor for transdermal delivery to the erectile tissue of the penis
EP1750766B1 (en) * 2004-05-11 2013-07-03 Emotional Brain B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
WO2008142396A1 (en) * 2007-05-18 2008-11-27 Anthony Denis Maher Methods of assessing male fertility using a uridine marker

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
HU9900438D0 (en) 1999-04-28
DE69921008T2 (de) 2006-02-02
EP0951908A2 (en) 1999-10-27
DE69921008D1 (de) 2004-11-18
ATE279194T1 (de) 2004-10-15
AU1839099A (en) 1999-09-09
NZ334333A (en) 2000-11-24
EP0951908A3 (en) 2000-08-16
ZA991393B (en) 2000-08-22
AU755402B2 (en) 2002-12-12
DK0951908T3 (da) 2004-12-27
IL128532A0 (en) 2000-01-31
TW542719B (en) 2003-07-21
US20060040935A1 (en) 2006-02-23
EP0951908B1 (en) 2004-10-13
CA2262268A1 (en) 1999-08-23
KR19990072798A (ko) 1999-09-27
HUP9900438A3 (en) 2002-01-28
ES2226281T3 (es) 2005-03-16
CA2262268C (en) 2003-07-29
HUP9900438A2 (hu) 2000-03-28
MY133446A (en) 2007-11-30
JPH11315025A (ja) 1999-11-16

Similar Documents

Publication Publication Date Title
PT951908E (pt) Metodo para o tratamento de impotencia devida a lesao da medula espinal
AR016993A1 (es) Formulaciones intranasales para tratar trastornos sexuales
ZA200206612B (en) Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction.
PT1073658E (pt) Inibidores de ogmp pdes de pirazolopirimidinona para o tratamento da disfuncao sexual
BR0316753A (pt) Método de tratamento para disfunção sexual
BR0108223B1 (pt) aparelho mecánico para o tratamento de impotência.
MX9703868A (es) Inhibidores de cgmp-pde para el tratamiento de disfuncion erectil.
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
WO1994004120A3 (en) Methods of treating sexual dysfunction in animals with and h agonist
AR032001A1 (es) Nuevo tratamiento
BR9810981A (pt) Medicamento contendo ioimbina e arginina para tratamento de disfunção erétil
PT1109814E (pt) 5-heterociclil pirazol¬4,3-d|pirimidina-7-onas para o tratamento da disfuncao erectil masculina
NO20055187D0 (no) Fremgangsmate for behandling og forebygging av lavere urinkanal symptomer
MXPA02012002A (es) Derivados de heterociclos y metodos de uso.
WO2004069254A3 (en) Use of dipyridamole or mopidamole for treatment and prevention of mmp-9-dependent disorders
WO2005051368A3 (en) Phosphodiesterase v inhibitor formulations
WO2002011665A3 (fr) Association d'une purine et d'un ains pour le traitement des dysfonctions sexuelles
MD1979F1 (en) Method of secondary cataract treatment
BR0313665A (pt) Utilização de bupropion para o tratamento da sìndrome das pernas inquietas
NO995008L (no) En transuretral anordning
BR0314364A (pt) Uso de inibidores de pde iv para tratar angiogênese
ES2092685T3 (es) Uso de atipamezol para el tratamiento de impotencia sexual masculina.
ECSP993027A (es) Formulaciones intranasales para trastornos sexuales
CA2203379A1 (en) Cgmp-pde inhibitors for the treatment of erectile dysfunction
ZA992793B (en) Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction.